Interim CEO Invests $50K in Open Market Purchase at Significant Premium
Summary
Hepion Pharmaceuticals' Interim CEO, Gary S. Stetz, purchased $50,000 worth of common stock at $0.04 per share, a substantial premium to the current market price of $0.0013, representing over 10% of the company's market cap.
Key Events
-
Interim CEO Makes Significant Purchase
Gary S. Stetz, Interim CEO and Director, acquired 1,250,000 shares of common stock for $50,000 in an open market transaction on April 21, 2026.
-
Purchase at Substantial Premium
The transaction was executed at $0.04 per share, which is significantly above the current market price of $0.0013.
-
Substantial Investment Relative to Market Cap
The $50,000 purchase represents approximately 10.5% of the company's current market capitalization.
-
Transaction Linked to Recent Private Placement
This purchase likely forms part of the $700,000 private placement at $0.04 per share, which was previously disclosed on April 22, 2026.
Analysis
This significant open market purchase by Interim CEO Gary S. Stetz demonstrates extremely strong conviction in Hepion Pharmaceuticals. On April 21, 2026, Mr. Stetz invested $50,000 to acquire 1,250,000 shares at $0.04 per share. This transaction, which appears to be part of the $700,000 private placement disclosed on April 22, 2026, represents over 10% of the company's market capitalization. The fact that the CEO purchased shares at $0.04, a price substantially higher than the current market price of $0.0013 (which is also near its 52-week high), indicates a strong belief in the company's long-term value despite recent market performance.
At the time of this filing, CTRVP was trading at $0.00 on OTC in the Life Sciences sector, with a market capitalization of approximately $476.4K. The 52-week trading range was $0.00 to $0.00. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.